Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAnna KalffMLMichael LöwJHJane S. Hocking

Discussion

Loading...

Member takes

Overview

Clinical trial finds added selinexor did not improve progression-free survival in patients post autologous stem cell transplant, suggesting increased toxicity risks.

Key Points

  • No significant benefit in progression-free survival was observed between maintenance therapies in multiple myeloma patients.
  • Among 149 patients, the complete response rate was higher in the selinexor group versus lenalidomide alone, yet led to more adverse events.
  • This phase III clinical trial randomized patients following autologous stem cell transplant for newly diagnosed multiple myeloma.
  • Findings indicate that the use of selinexor in maintenance therapy may be limited due to toxicity and side effects.

Cite This Study

Kalff et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da99https://doi.org/10.1182/blood-2025-4039
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial2025
  2. 2Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial.2026 · 2 citations
  3. 3The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma2025
  4. 4Safety and efficacy of selinexor sequential azacytidine in newly diagnosed patients with myelodysplastic syndromes EB1 or EB2: A single-center, single-arm, phase ib/II trial2025
  5. 5Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS2025